,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2019-09-21 16:00:00,Shares of life sciences technologist and software provider Veeva Systems (NYSE: VEEV) have been a big winner for the last few years.,0.9316643476486206,0.016155989840626717,0.05217965692281723,positive,0.9155083298683167
1,2019-09-21 16:00:00,"They've gained 400% over the last five-year stretch, and owning them has been one of the best ways to play the pharmaceuticals and biotech industry.",0.7957920432090759,0.012634736485779285,0.19157321751117706,positive,0.7831572890281677
2,2019-09-21 16:00:00,"Even after an epic run, Veeva continues to put up solid double-digit sales growth and even faster profitability expansion, and the cloud-based software firm also reached a revenue milestone well ahead of schedule.",0.9512518644332886,0.01913190260529518,0.029616206884384155,positive,0.9321199655532837
3,2019-09-21 16:00:00,"On the heels of a recent software stock pullback and with digital transformation taking center stage, now looks like a good time to buy in or add to positions.",0.7975865006446838,0.02135942131280899,0.1810540407896042,positive,0.7762270569801331
4,2019-09-21 16:00:00,There will be plenty of ways for Veeva Systems to grow even more in the next five years.,0.7830421328544617,0.011521652340888977,0.20543618500232697,positive,0.7715204954147339
5,2019-09-21 16:00:00,"Veeva provides various cloud-delivered software services like data management, regulatory compliance tools, and customer relationship management for pharmaceutical and biotech companies.",0.026712767779827118,0.005583032965660095,0.9677042365074158,neutral,0.021129734814167023
6,2019-09-21 16:00:00,"Biotech is fraught with unique challenges that make the industry especially volatile, and Veeva has been a comparatively stable way to invest in the space.",0.5244256258010864,0.01080385036766529,0.46477052569389343,positive,0.5136217474937439
7,2019-09-21 16:00:00,"Sales are growing fast, and as they do, gross profit margin on services sold is improving as well -- indicating Veeva has yet to reach optimal scale.",0.953542947769165,0.021943483501672745,0.024513494223356247,positive,0.9315994381904602
8,2019-09-21 16:00:00,"Revenue has even accelerated slightly so far during the 2020 fiscal year, up 26% compared with 25% during the 2019 fiscal year.",0.9546160101890564,0.021701062098145485,0.023682918399572372,positive,0.9329149723052979
9,2019-09-21 16:00:00,"Operating expenses are of course also growing, but at a slower pace.",0.056030161678791046,0.45552903413772583,0.4884408414363861,neutral,-0.3994988799095154
10,2019-09-21 16:00:00,"It all adds up to a technology platform that is maturing, and as it does so, sales are getting converted into big bottom-line gains.",0.8512925505638123,0.014522761106491089,0.13418464362621307,positive,0.8367698192596436
11,2019-09-21 16:00:00,"In terms of free cash flow (basic profits, measured by subtracting cash operating expenses and capital expenditures from revenue), the above chart equates to huge gains for the shareholders.",0.9408494234085083,0.019047090783715248,0.040103454142808914,positive,0.9218023419380188
12,2019-09-21 16:00:00,"Granted, the increased cash flow means Veeva trades at premium pricing -- trailing 12-month price to free cash flow is at 58.1 as of this writing -- as the market is anticipating this well-above-average pace of growth will continue for the foreseeable future.",0.9296945333480835,0.014922832138836384,0.05538259446620941,positive,0.9147716760635376
13,2019-09-21 16:00:00,Is that an unrealistic expectation?,0.054945629090070724,0.19208768010139465,0.7529667019844055,neutral,-0.13714204728603363
14,2019-09-21 16:00:00,"A robust product pipeline that keeps getting better

Global spending on digital transformation is expected to grow well into the double digits for the foreseeable future, and pharmaceutical, biotech, and medical device companies aren't exempt from the transition.",0.8215435743331909,0.019287094473838806,0.15916942059993744,positive,0.8022564649581909
15,2019-09-21 16:00:00,"During the summer of 2019, Veeva reported that its product suite Vault -- a comprehensive collection of apps and data management tools -- surpassed 50% of total revenue.",0.9054313898086548,0.01253807358443737,0.08203054964542389,positive,0.8928933143615723
16,2019-09-21 16:00:00,"This milestone was a year and a half ahead of schedule according to management, and has years of growth ahead of it as life science businesses continue to look for ways to update their business models for the 21st century.",0.8662325143814087,0.014876279048621655,0.11889120936393738,positive,0.8513562083244324
17,2019-09-21 16:00:00,"CEO Peter Gassner had this to say about his company's marquee product:

Vault now has nearly 650 customers and as of Q2 represents more than 50% of total revenue.",0.09473767131567001,0.0072604697197675705,0.8980018496513367,neutral,0.0874771997332573
18,2019-09-21 16:00:00,This is an exciting milestone.,0.7315903306007385,0.01325045246630907,0.2551591992378235,positive,0.7183398604393005
19,2019-09-21 16:00:00,"When we started Vault a number of years ago, the potential was clear to me.",0.21005208790302277,0.010626166127622128,0.7793217301368713,neutral,0.19942592084407806
20,2019-09-21 16:00:00,And as I look ahead it's also clear that we are in the early days of Vault.,0.25783252716064453,0.04840061813592911,0.6937668919563293,neutral,0.20943191647529602
21,2019-09-21 16:00:00,"This quarter, a newly independent top-20 medical device company standardized on Vault across the organization, including clinical, quality, regulatory, and commercial.",0.48989659547805786,0.00978867057710886,0.5003147125244141,neutral,0.4801079332828522
22,2019-09-21 16:00:00,With the ability to start from a clean slate they chose Vault because it's the only solution to provide best-in-class application suites on a single modern cloud platform.,0.46848544478416443,0.012645184993743896,0.5188693404197693,neutral,0.45584025979042053
23,2019-09-21 16:00:00,"Within the range of available Vault customizable suites, Gassner added that Vault CTMS -- geared toward companies managing clinical trials and process management for new treatment development -- is gearing up to be an industry-leading software solution as regulatory demands increase for biotechs over time.",0.8645380139350891,0.012080978602170944,0.12338100373744965,positive,0.8524570465087891
24,2019-09-21 16:00:00,"Other highlights include Veeva's customer relationship management (CRM), which has also been getting put to use by global pharmaceutical distributors.",0.7826144695281982,0.011243474669754505,0.2061421275138855,positive,0.7713710069656372
25,2019-09-21 16:00:00,"In this department specifically, Veeva battles with salesforce.com (NYSE: CRM) and its own selection of digital tools for life sciences.",0.031072692945599556,0.8616902232170105,0.1072370633482933,negative,-0.8306175470352173
26,2019-09-21 16:00:00,"But Veeva's laser focus on the life sciences industry and solutions that round out CRM has helped it win expanded relationships with customers in spite of competition from the likes of Salesforce, Cerner (NASDAQ: CERN), and others.",0.9494624733924866,0.017245139926671982,0.03329238295555115,positive,0.9322173595428467
27,2019-09-21 16:00:00,It has built out arguably the most comprehensive suite of software tools to help life science companies bridge the gap between old legacy operations and the digitally driven operations of the future.,0.6893980503082275,0.012008915655314922,0.29859301447868347,positive,0.6773891448974609
28,2019-09-21 16:00:00,"In five years' time, it's safe to say Veeva will have quite a few more customers than it does today, and its high profit margins mean new sales should continue to convert to an even higher bottom-line increase over time.",0.942088782787323,0.015758784487843513,0.04215250536799431,positive,0.9263299703598022
29,2019-09-21 16:00:00,"Owning Veeva remains one of the best ways to bet on the world of healthcare and biotechnology, in spite of the high price tag.",0.3950483202934265,0.012135823257267475,0.5928158164024353,neutral,0.3829124867916107
30,2019-09-21 16:00:00,"10 stocks we like better than Veeva Systems

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen.",0.12699975073337555,0.025114860385656357,0.8478853702545166,neutral,0.1018848866224289
31,2019-09-21 16:00:00,"After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.",0.8087436556816101,0.0373060368001461,0.15395022928714752,positive,0.7714376449584961
32,2019-09-21 16:00:00,"*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Veeva Systems wasn't one of them!",0.20886248350143433,0.015013301745057106,0.7761241793632507,neutral,0.19384917616844177
33,2019-09-21 16:00:00,That's right -- they think these 10 stocks are even better buys.,0.8146857619285583,0.02307075634598732,0.16224350035190582,positive,0.7916150093078613
34,2019-09-21 16:00:00,Nicholas Rossolillo and his clients own shares of Salesforce.com.,0.011972276493906975,0.01109510287642479,0.9769326448440552,neutral,0.0008771736174821854
35,2019-09-21 16:00:00,The Motley Fool owns shares of and recommends Salesforce.com and Veeva Systems.,0.03005971759557724,0.018141884356737137,0.9517984390258789,neutral,0.011917833238840103
36,2019-09-21 16:00:00,The Motley Fool has the following options: long January 2021 $100 calls on Salesforce.com.,0.014087560586631298,0.06427516788244247,0.9216372966766357,neutral,-0.0501876063644886
37,2019-09-21 16:00:00,The Motley Fool recommends Cerner.,0.07089276611804962,0.0261527206748724,0.9029545187950134,neutral,0.044740043580532074
38,2019-09-21 16:00:00,The Motley Fool has a disclosure policy.,0.016547108069062233,0.01730392687022686,0.9661489725112915,neutral,-0.0007568188011646271
